The New Frontier - Your weekly science and innovation update – 11th November 2026

Oxford, three ways

AbbVie opened an expanded 12,000 sq ft R&D facility in Oxford on Wednesday as part of more than £120 million it is investing in UK research, academic collaborations and talent. The site builds on its 2022 purchase of Oxford-founded DJS Antibodies and will concentrate on immunology, neuroscience and oncology; the company already employs over 1,100 people across Oxford, Maidenhead and Marlow. It follows last week’s £1 billion Budget package from Convatec, Vertex and Kindeva.

Vertex has chosen Harwell for a 155,000 sq ft research facility, to be built next to the new CO:LABS building in the campus's Accelerator Quarter with construction pencilled in for early 2027, subject to planning. Since its launch in 2016, Harwell’s Health Tech cluster has grown to over 75 life sciences organisations and 1,400 people.

Oxford University spin-out FluoRok closed a $30 million Series A on Thursday, led by Orano Venture Fund, with Oxford Science Enterprises, BGF and the University also investing. The company has developed a hydrofluoric-acid-free process for producing fluorochemicals used in lithium-ion batteries and pharmaceuticals. The capital will fund demonstrator facilities for reagents and electrolyte salts as FluoRok scales towards becoming the EU’s first domestic producer of a key battery electrolyte salt. FluoRock says that approximately one in five medicines and one in five agrochemicals on the market contain fluorine. This highlights the growth potential of companies supplying materials and components into sectors such as life sciences, particularly as sustainability, supply-chain resilience, sovereignty and security move to the heart of UK policy.

Cambridge's $2.5 billion year

Cambridge human-cell manufacturer bit.bio closed a $25 million Series D on Wednesday from M&G Investments and Abcam founder Jonathan Milner, ten months after its $50 million Series C. The numbers behind it are striking: paid vial volumes up 76% this year, orders up 34%, active customers up 40%. The company says it will spend the money on products and customers.

Zoom out and Business Weekly's tally puts Cambridge technology and life sciences fundraising at almost $2.5 billion in the twelve months to 29 October, with 2026 year-to-date running 34% ahead of last year on the back of AI, defence tech and oncology money.

The small print

The Budget promised “the most pro-business migration system in Europe for highly skilled workers”, providing the labour market counterpart to its investment in laboratories and research infrastructure. Measures include restoring the Graduate visa to two years for graduates of qualifying universities, expanding the High Potential Individual route from the world’s top 100 to 150 universities, and reducing occupation-specific salary thresholds from median earnings to the 25th percentile from spring 2027. However, the general £41,700 salary floor will rise with earnings. Employers’ Immigration Skills Charge and sponsorship fees will also no longer be treated as taxable benefits for workers, according to Pinsent Masons.

From 2027, the highest-skilled sponsored workers who lose their jobs will have up to six months to find a new sponsor, compared with 60 days today. This could help retain mobile scientists and engineers when a start-up fails, funding falls through or a research programme ends. However, eligibility will depend on definitions of “highest skilled” and “highly paid” that have yet to be published.

The catch is the removal of the PhD salary discount and the Dementia Researcher has run the numbers. This will leave many sponsored research roles subject to the general salary threshold. Grade 7 postdoctoral positions currently paying £38,448 to £41,064 already sit below the £41,700 floor, which is due to rise. Some entry-level research jobs could therefore become unsponsorable. This matters when approximately 19% of the UK’s R&D workforce is international, including around 70% of postdocs at the Wellcome Sanger Institute and 44% of staff at the Francis Crick Institute. The expanded Global Talent route, which has no general salary threshold, offers a partial alternative and will open to more R&D-intensive businesses in Industrial Strategy sectors by spring 2027.

The new “earned settlement” framework sharpens this divide. The standard route to indefinite leave to remain will increase from five to ten years, although workers earning more than £50,271 in three of the preceding five years could qualify after five years. Those earning at least £125,141 in three of the preceding four years, alongside eligible Global Talent applicants, could qualify after three. The detailed Immigration Rules have not yet been published, so existing arrangements remain in place for now. A researcher earning £40,000 may be undertaking strategically important work in genomics, quantum or advanced materials, yet face a ten-year settlement journey while a considerably better-paid employee qualifies after five.

This exposes the risk of policymaking in silos: measures designed to attract investment in one area could be undermined by changes elsewhere in the system.

Sequoia goes home

Sequoia is closing its London office as part of a wider restructuring that will flatten its partnership, combine investment teams and close its Arc accelerator and Scouts programme. The retreat comes despite roughly $10 billion of fresh funding.

For the UK, the symbolism matters. Overseas investors provided 74% of UK venture funding in 2025, and physical proximity can be particularly important at pre-seed and seed, when investment decisions rely as much on relationships, networks and judgement as financial evidence.

But an office closure does not necessarily mean a retreat from Europe. Sequoia's experience in Israel shows that its relationship with an ecosystem can continue, and later deepen, without a permanent local office.

The question is therefore not whether Sequoia has a London postcode, but whether it continues to find and fund European companies early. Global investors can finance Europe's obvious winners from California. Spotting them before they become obvious is harder.

Exhibit A: Station F

Paris's Station F published its Future 40 and announced that companies from its campus have raised a record €2 billion so far in 2026, up from €1.5 billion in 2025, helped by two alumni mega-rounds. The Future 40 are the top 4% of the thousand-plus start-ups on site.

It is worth being precise about why the model works. The physical proposition is a single 34,000 sq m (370,000 sq ft) converted 1929 rail freight shed beside Gare d'Austerlitz with 3,000 desks and room for 1,000 companies bought and fitted out by Xavier Niel, who put around €300 million of his own money in and hired a former Sequoia scout, Roxanne Varza, to run it. Around 40 programmes sit under the roof, roughly a third run by corporates (Microsoft, TotalEnergies; Samsung's computational design lab has just moved in), a third by universities and a third by ecosystem players. The corporates pay in kind: Microsoft gives each of its selected companies $350,000 of Azure credits, which is why a Founders Program desk costs €259 a month. More than 30 venture funds are formally part of the community and advertise themselves on a wall in the 'Share' hall, next to desks staffed by the tax office, the social-security agency and the public funding bodies, so a founder can sort a grant, a tax query and a payroll registration without leaving the building. Six hundred co-living flats handle the housing problem. And it is deliberately a tourist attraction: heads of state, a thousand events a year, a Jeff Koons in the atrium and a 4,500 sq m Big Mamma food hall open to the public.

Lessons from Station F

• Aim for scale and bring everyone under one roof. Including startups, corporates and universities.
• Build strong links with the wider ecosystem, and keep powerful players in close proximity to have a high concentration of well-known brands and partners.
• Establish deep connections with the government. Give it something to champion and show how you can help deliver on its goals.
• Think outside the box (and borders). Leverage it to add value to the ecosystem beyond multiplying startups – be it through building international links, consulting work, or getting every person visiting the building, no matter who they are, to care about startups.
• Regularly review your offerings and partnerships. Ensure you address the changing needs of founders and the ecosystem.

Unsticking the sites

Quietly, on Monday, Business Secretary Jonathan Reynolds launched the Strategic Sites Accelerator: around £700 million of equity, debt and targeted grants, run by the Office for Investment and the National Wealth Fund with CBRE as national delivery partner, to get six to ten of the country's biggest stalled industrial and commercial sites moving and crowd in up to £2 billion of private money. The criteria reflect the familiar blockers: finance, grid connections, planning and viability. The government has explicitly identified science parks, manufacturing sites and innovation districts as priorities for funding, particularly across advanced manufacturing, digital and technology, defence and life sciences. Engagement is already under way in Glasgow, Burgess Hill and Sheffield, with Place North West reporting conversations across Greater Manchester, West Yorkshire, the West Midlands, Liverpool, the North East and the Cardiff Capital Region. Mayors get a share of business rates from 2027 and income tax from 2028 to help carry the running costs. No timetable has been published for naming the sites, which means a good deal of lobbying in the meantime.

Quantum leap, quantum leak

Universal Quantum's Sebastian Weidt chose the week of the national quantum technologies showcase to warn in City AM that Britain could lose its remaining home-grown quantum companies to overseas rivals within about two years unless ministers change course. His Sussex spin-out raised a $100 million Series A this autumn, the UK’s largest in quantum, but most of the capital came from overseas, while its €67 million of hardware contracts are with the German Aerospace Center rather than Whitehall. His asks are familiar: public equity stakes, public procurement that prefers domestic developers, and a dedicated quantum minister alongside the AI one.

Scotland, meanwhile, made its pitch loudly: 40% of UK quantum research over the past decade, leadership of two of the five national hubs, a critical-technologies supercluster of 160 companies and 11,500 jobs, and a projected £10 billion of turnover by 2035. This came in addition to several UK advancements:

• A new Quantum Centre for Nuclear Defence and Security at the Atomic Weapons Establishment (AWE). 
• Operational prototype quantum computing testbeds run by the National Quantum Computing Centre.
• A £14 million award for 14 industry-led projects focused on next-generation quantum sensors.
• Analysis suggests that by 2045, quantum technologies could contribute £11 billion to UK GDP and support 100,000 jobs.

In other news...

Offshore-wind software firm Kinewell Energy has relocated to The Catalyst at Newcastle Helix after raising over £1 million.

UK companies took €1 billion of the €1.3 billion invested across Europe's 60-plus venture deals last week.

Manufacturing Chemist weighs what the Budget means for pharma manufacturers – VAT relief on free medicines and revised capital allowances in the plus column, labour costs and most big decisions deferred to the 2027 Spending Review in the minus.

Scottish Widows, Aberdeen Investments and IP Group announced the first investments from a Scottish Widows growth long-term asset fund that channels workplace pension savings into UK venture growth: Oxford Quantum Circuits, Quantum Motion, battery developer Nyobolt and Oxford's Genomics Limited. Amounts were not disclosed, but it is one of the first UK pension schemes to put members' money into domestic venture growth, and Aberdeen's Nalaka De Silva framed it as the patient domestic capital that British science has lacked.

Cardiff and Swansea universities signed a memorandum of understanding on Monday to explore the UK's first multi-institution compound-semiconductor pilot foundry, knitting together Cardiff's Institute for Compound Semiconductors and Swansea's £55 million Centre for Integrative Semiconductor Materials so that companies in the South Wales cluster can prototype and prove technology at pilot scale before committing to volume fabs.

London advanced-materials company Elethron plans to establish UK manufacturing of aluminium nitride substrates – the ultra-wide-bandgap material behind high-power electronics, satellite-communications RF and deep-UV devices – starting with 2-inch wafers for customer trials and a pathway to 4-inch. Its founder's pitch is sovereignty: the UK currently depends on foreign and 'challenged' supply chains for wide-bandgap materials. No site has been named.